Reported Saturday, BioMarin Presents Real-World Data On VOXZOGO Efficacy And Safety In Children With Achondroplasia At ESPE 2024

Benzinga41minutes ago

U.S. Pharma Is Largely Immune From 'MAHA' Impact: Wolfe

Seeking AlphaNov 16 03:29

The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical

BenzingaNov 15 20:00

BioMarin Pharmaceutical Initiated at Outperform by Wolfe Research

Dow JonesNov 15 18:26 · Ratings

Biomarin Pharmaceutical Analyst Ratings

BenzingaNov 15 18:15 · Ratings

Wolfe Research Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Cuts Target Price to $95

Futu NewsNov 15 05:31 · Ratings